|Year : 2021 | Volume
| Issue : 1 | Page : 56-61
A comparison of radiotherapy treatment planning techniques in patients with rectal cancers by analyzing testes doses
Evrim Duman1, Yılmaz Bilek1, Gokay Ceyran2
1 Department of Radiation Oncology, University of Health Sciences Antalya Education and Research Hospital, Antalya, Turkey
2 Department of Radiation Oncology, University of Health Sciences Adana City Training and Research Hospital, Adana, Turkey
|Date of Submission||12-May-2019|
|Date of Decision||10-Aug-2019|
|Date of Acceptance||23-Oct-2019|
|Date of Web Publication||09-Oct-2020|
Department of Radiation Oncology, University of Health Sciences Antalya Education and Research Hospital, Antalya
Source of Support: None, Conflict of Interest: None
Purpose: To evaluate the target volume (TV) and critical organ doses with priority of testes with the comparison of conformal radiotherapy (CRT), dynamic intensity-modulated radiotherapy (DIMRT), and volumetric modulated arc therapy (VMAT) techniques.
Materials and Methods: CRT, DIMRT, and VMAT techniques were generated on computed tomography images in prone position of 10 male patients with distal rectal cancer. Conformity index (CI), heterogeneity index (HI), treatment time, and monitor units were examined; dose-volume-histograms (DVHs) for the TV and the organs at risk (OARs) were evaluated.
Results: Target dose coverage of all treatment plans was similar. HI and CI values for DIMRT and VMAT were closer to “1” compared to CRT. DVH parameters for OARs were decreased with DIMRT and VMAT compared to CRT. The percent volume (Vx) of 3 Gy dose of testes was 62.01% (±25.45%), 42.68% (±16.42%), and 35.89% (±14.97%) in the CRT, DIMRT, and VMAT techniques, respectively. V3 of testes decreased with VMAT compared to CRT and DIMRT (P = 0.008 and P = 0.051, respectively).
Conclusion: Modern radiotherapy techniques are superior to conformal techniques in planning quality parameters and sparing OARs. DIMRT and VMAT could be considered instead of CRT in the desire to preserve fertility of patients with rectal cancer.
Keywords: Intensity-modulated radiotherapy, rectal cancer, testes dose, volumetric modulated arc therapy
|How to cite this article:|
Duman E, Bilek Y, Ceyran G. A comparison of radiotherapy treatment planning techniques in patients with rectal cancers by analyzing testes doses. J Can Res Ther 2021;17:56-61
|How to cite this URL:|
Duman E, Bilek Y, Ceyran G. A comparison of radiotherapy treatment planning techniques in patients with rectal cancers by analyzing testes doses. J Can Res Ther [serial online] 2021 [cited 2021 Apr 17];17:56-61. Available from: https://www.cancerjournal.net/text.asp?2021/17/1/56/297619
| > Introduction|| |
Colorectal cancer is the third most commonly diagnosed cancer, with a 10.9% worldwide incidence per year in males. Rectal cancers constitute approximately one-third of all colorectal cancers, and the cumulative incidence risk of a male for rectal cancer is 1.2% from birth to 74 years.,
The primary treatment for a potential curative disease is surgery, and the addition of radiotherapy and chemotherapy improves the local control rates in patients with a risk of local recurrence. Neoadjuvant chemoradiotherapy before surgery has become the standard treatment in patients with locally advanced rectal cancer. Neoadjuvant chemoradiotherapy often reduces the local recurrence risk of resectable tumors, downstages the tumor, and improves resectability in most of the unresectable tumors.,
Radiotherapy is currently recommended for many patients, and long-term survival after modern multimodal treatment is expected in at least 60% of patients with rectal cancer. Although the most common side effect related to radiotherapy is intestinal toxicity, sexual dysfunction is one of the problems encountered, especially during prolonged survival.,,,,, Lower serum testosterone and lower calculated free-testosterone values have been reported in patients who have been irradiated.
Testicular function loss is especially prevalent in distal rectum tumors due to proximity of the testes to the radiotherapy treatment area. The testes are outside the target radiation volume in most patients, but they can still be exposed to scattered radiation. Although radiotherapy-induced testicular damage is related to the testicular dose of irradiation, the radiation dose limit for the testis has not been clearly defined., The germinal epithelium of the testis is very sensitive to radiation-induced damage, and the changes in spermatogonia occur after as little as 0.1 Gy. The number of spermatogonia reduces progressively over 21 weeks to their minimum levels after single radiation doses between 0.2 and 4 Gy. The recovery process depends on the dose of radiation. The ejaculated sperm count begins to increase at 7 months after irradiation with a single dose of 1 Gy, and it takes about 2 years to reach pre-irradiation levels. Radiation-fractionated doses of ≥2 Gy to the testis can cause permanent azoospermia. Currently, sperm banking remains the only proven method in males treated with pelvic radiotherapy.
Side effects related to radiotherapy can be reduced using advanced treatment methods and devices. Intensity-modulated radiotherapy (IMRT) reduces acute and late toxicity compared to conformal radiotherapy (CRT), by limiting the radiation dose delivered to surrounding organs.,, Volumetric modulated arc therapy (VMAT) with gantry rotation provides a more homogeneous dose distribution compared with IMRT at shorter treatment times. VMAT treatment in patients with locally advanced rectal cancer has the potential to substantially reduce high-grade acute and late toxicity without impairing short-term oncological results. In this study, we aimed to evaluate the target volume (TV) and critical organ doses with the testes by comparing 3-field CRT, 5-field dynamic intensity-modulated radiotherapy (DIMRT), and VMAT in patients with distal rectal cancers.
| > Materials and Methods|| |
Ten men with rectum cancer who were treated with neoadjuvant chemoradiotherapy between March 2016 and August 2016 were included in this study. Inclusion criteria included patients with tumors located in the distal rectum (the first 10 cm from the anal verge) and patients with T3N1-2 disease. Large tumors invading the bladder, prostate, or pelvic lateral wall and tumors located in the proximal rectum extending to the sigmoid colon were excluded from the study. Treatment planning tomography images of the patients were re-evaluated retrospectively.
This study was approved by the Institutional Ethics Committee.
Simulation and contouring
Patients were immobilized in the prone position using a belly board. Computed tomography (simCT, Aquilion-LB; Toshiba, Tokyo, Japan) images were obtained using a 3-mm slice thickness without intravenous and oral contrast. The entire pelvis, from the upper abdomen to 2 cm below the scrotum, was included in the images.
In each patient, the primary tumor region was contoured as the gross tumor volume (GTV) with the help of positron emission tomography–computed tomography and pelvic magnetic resonance images. Clinical tumor volume-1 (CTV-1) was obtained by adding 20-mm margins in all directions to the GTV. CTV-2 contained regional lymph nodes (internal iliac, external iliac, and presacral lymph nodes) in addition to CTV-1. Five-millimeter margins were added in all directions to create planning target volume-1 (PTV-1) and PTV-2. Bladder, bilateral femoral heads, and small intestines surrounding the PTV-2 were outlined as organs at risk (OARs). There was a testis cavity on belly board and testes were contoured in the scrotum to assess the doses that were exposed.
Three different techniques were used for each patient. In 3-field CRT plans, 0°, 90°, and 270° gantry angles were used with 18 MV photon energy. A total of 46 Gy of radiotherapy was planned for PTV-2 with 2 Gy fractional doses using 5-day weekly standard fractionation, and a 4 Gy boost was administered to PTV-1 to complete the total dose to 50 Gy. In 5-field DIMRT, 0°, 50°, 100°, 260°, and 310° gantry angles were used. VMAT was designed as a double partial arc starting at 270° and ending at 90°. A simultaneous integrated boost technique was used with 6 MV photon energy to perform both DIMRT and VMAT plans in 25 fractions for a total dose of 46 Gy for PTV-2 and 50 Gy for PTV-1.
The CMS Monaco 5.1 treatment planning system was used for all techniques. It was used for each plan, and 98% of the TV was used to cover 95% of the prescribed dose. OAR doses were kept below the QUANTEC tolerance limits. It was aimed to be <50% of the volume of the testes in the 3 Gy isodose line recommended in the Radiation Therapy Oncology Group (RTOG)-0630 study to evaluate the testes dose. In DIMRT and VMAT, the same dose constraints were used.
Treatment plan evaluation
Dose distributions in transverse, sagittal, and coronal slices for all plans were visually checked, and dose-volume-histograms (DVHs) were evaluated in terms of PTV and OARs. Since the major concern with IMRT and VMAT is low-dose volumes receiving higher doses than CRT, the percent volume (Vx) of the 2 Gy and 1 Gy doses for the testes was evaluated. In addition, the V0.1 for testes was evaluated because of its impact on changes in spermatogonia.
Conformity index (CI) and heterogeneity index (HI) were calculated. The CI and HI formulae are shown in Equation 1 and Equation 2, respectively. The monitor unit (MU) of each plan was examined. Beam-on times for VMAT and DIMRT were evaluated on the treatment planning system and were defined as the treatment times.
The CI calculation is shown where PIV was the reference iso-dose volume. The TV was equal to PTV-1. TVPIV was TV covered by the reference iso-dose. The CI value calculated as “1” was an ideal plan.
The HI calculation is shown. The high- and low-dose percentages in related structures were defined as X and Y, respectively. It was recommended in the International Commission of Radiation Unit-83 report to use 98% of the prescribed dose as the low-dose percentage and 2% of the prescribed dose as the high-dose percentage. The HI value indicated as “1” was an ideal plan.
SPSS software, version 21 (IBM, Armonk, NY, USA) was used for the statistical analyses. The Friedman test and Wilcoxon signed-rank test were performed to analyze the variations between three different technique groups. A P < 0.05 was considered statistically significant.
| > Results|| |
The mean PTV-1 and PTV-2 covered by the 95% isodose line are summarized in [Table 1]. There was no statistically significant difference between CRT, DIMRT, and VMAT for dose coverage of PTV, except for the dose distribution using VMAT, which was better than CRT for PTV-1 (P = 0.028).
|Table 1: Mean planning target volume 1 and planning target volume 2 volumes covered by the 95% isodose line, conformity index, heterogeneity index, monitor unit, and treatment time values for 3-field conformal radiotherapy, 5-field dynamic intensity-modulated radiotherapy, and volumetric modulated arc therapy techniques|
Click here to view
The mean HI and CI values for all three plans are shown in [Table 1]. Although there was no statistically significant difference between HI values for DIMRT and VMAT (P = 0.65), they were significantly better than those of CRT (P = 0.011 and P = 0.007, respectively). The CI values were closer to “1” using DIMRT when compared with CRT and using VMAT when compared with DIMRT (P = 0.005 and P = 0.018, respectively).
The MU values for CRT, DIMRT, and VMAT are summarized in [Table 1]. The MU values were significantly higher for CRT than for DIMRT and VMAT (P = 0.005 and P = 0.005, respectively). The mean segment numbers for DIMRT and VMAT were 95 and 168 (±5), respectively. Treatment times for the DIMRT and VMAT plans are shown in [Table 1]. While the MU values for VMAT were higher than those for DIMRT, the treatment times were lower (P = 0.007 and P = 0.005, respectively).
The DVH evaluations for the bladder, small intestine, bilateral femoral heads, and testes are summarized in [Table 2].
|Table 2: Dose-volume-histogram values of organs at risk in the 3-field conformal radiotherapy, 5-field dynamic intensity-modulated radiotherapy, and volumetric modulated arc therapy techniques|
Click here to view
The percent volume (Vx) of the 45 Gy dose for the bladder was decreased for DIMRT compared with CRT and decreased for VMAT compared with DIMRT (P = 0.007 and P = 0.028, respectively).
The V40 value for the small intestine was decreased for DIMRT and VMAT compared with CRT (P = 0.005 and P = 0.005, respectively). When comparing DIMRT and VMAT, a statistically significant difference was found in favor of VMAT (P = 0.022). Similar results were found for V45 values for the small intestine. VMAT provided the best protection for the small intestine when compared with CRT and DIMRT (P = 0.005 and P = 0.022, respectively). The maximum point dose (Dmax) for the small intestine was lower for DIMRT and VMAT when compared with CRT (P = 0.005 and P = 0.005, respectively).
With respect to the Dmax values for the right femoral heads, VMAT and DIMRT were superior to CRT (P = 0.013 and P = 0.022, respectively). In a similar manner, the decrease in Dmax values for the left femur observed for VMAT and DIMRT was statistically significant when compared with CRT (P = 0.007 and P = 0.017, respectively). For both femurs, there was no difference between DIMRT and VMAT (P = 0.87 and P = 0.33, respectively).
Similar results were found for V0.1 values for the testes. There was no statistically significant difference between V1 values for CRT, DIMRT, and VMAT (P = 0.097). The V2 value for the testes was decreased for DIMRT and VMAT compared with CRT (P = 0.009 and P = 0.007, respectively). When comparing DIMRT and VMAT, no statistically significant difference was found (P = 0.3). Comparison of V3 values for the testes revealed a statistically significantly decrease for DIMRT and VMAT when compared with CRT (P = 0.008 and P = 0.008, respectively) [Figure 1]. It was decreased by nearly 50% after VMAT compared with CRT. There was a 15.9% decrease in V3 values for the testes after VMAT compared to DIMRT, but it did not reach statistical significance (P = 0.051). Differences between the 3 Gy dose areas of the treatment techniques in the transverse sections of the tomography images of patients with rectal cancers are shown in [Figure 2].
|Figure 1: The percent volumes of 3 Gy doses (V3) for testes in 10 patients. CRT = Conformal radiotherapy, DIMRT = Dynamic intensity-modulated radiotherapy, VMAT = Volumetric modulated arc therapy|
Click here to view
|Figure 2: The 3-Gy dose volume differences obtained by subtracting treatment plans from each other (red line). CRT − VMAT: Conformal radiotherapy minus volumetric modulated arc therapy, CRT − DIMRT: Conformal radiotherapy minus dynamic intensity-modulated radiotherapy, DIMRT − VMAT: Dynamic intensity-modulated radiotherapy minus volumetric-modulated arc therapy. The highlighted green denotes the testes, and the highlighted orange line denotes the planning target volume-2|
Click here to view
| > Discussion|| |
Three-dimensional CRT still remains the main modality of radiotherapy for patients with rectal cancers, in many institutions. Larger treatment volumes affect the acute and late toxicities of radiotherapy and the quality of life. IMRT could be considered as the best choice of treatment planning to minimize toxicity. VMAT is another radiation technique that has a shorter beam-on time and more homogenous dose distribution compared with IMRT. A few studies have addressed the use of VMAT in rectal cancer with 360° arc rotation and compared it with CRT and IMRT.,, A double arc technique was used in this study with a 270°-beginning and 90°-ending to minimize the dosimetry effect of the belly board and to prevent the small intestine from entering the treatment field.
Shi et al. assessed the dosimetry difference between IMRT and VMAT in patients with rectal cancer undergoing radiotherapy after resection. They concluded that the dose distribution of VMAT was equal to or superior to IMRT. Although our results showed that PTV dose coverages were similar for PTV-2, a statistically significant change was only found between CRT and VMAT for PTV-1, with VMAT being more favorable. Target dose coverages of DIMRT and VMAT were found to be similar for both PTV-1 and PTV-2.
The CI formula, which is defined by the RTOG and suggested in the International Commission of Radiation Unit-83 report, is a useful adjunct for the evaluation of techniques. The CI formula, which was used in this study, takes both the PTV and extra-PTV organs into consideration and currently has the widest range of utilization as a comparison index. In a study reported by Wen et al., CRT, IMRT, and VMAT were compared, and dosimetry analyses demonstrated that IMRT was superior to CRT in the conformity and homogeneity of the dose distribution. According to CI results in our study, CRT was the poorest, and although DIMRT and VMAT showed similar results, VMAT was significantly better.
Dose homogeneity characterizes the uniformity of the absorbed dose distribution in the TV. The HI is defined as a tool for evaluating dose changes in the TV, such as HI. Our results showed that the HI values were similar for both DIMRT and VMAT and closer to 1, when compared with CRT.
Shortening the treatment time reduces both the errors caused by the patient's movements during treatment and the errors caused by the internal organ movements. Treatment time can be shorter with VMAT than with IMRT, because of more beam entry angles in VMAT. In our study, the treatment time was shorter with VMAT than with DIMRT, as expected. Although MU values affect the treatment times during comparison of same treatment techniques, they do not directly affect the treatment times during comparison of different treatment techniques, such as CRT, DIMRT, and VMAT. In our study, MU values were high for CRT because wedges were used. The treatment time was shorter with VMAT than with IMRT, despite higher MU values.
Wen et al. compared CRT, 5-field IMRT, and VMAT in patients with locally advanced rectal cancers undergoing preoperative radiotherapy and concluded that IMRT was superior to CRT in providing better OAR protection. Zhao et al. compared CRT, IMRT, and VMAT, which were planned with a simultaneous integrated boost for locally advanced rectal cancers, and concluded that although IMRT and VMAT achieved comparable target coverages, IMRT was better for OARs and in sparing normal tissues. Shi et al. reported that VMAT offers better small intestine protection with decreased treatment times, compared with IMRT. In our study, VMAT was better than DIMRT in protecting the small intestine and bladder, and DIMRT was better than CRT. Although there was no difference between VMAT and DIMRT, they were both superior to CRT for protection of left and right femurs.
There has been no dose range defined in the literature for the testes in patients treated with pelvic radiotherapy. The cumulative average radiation dose received by the testes was found to be 8.4 Gy in a study by Dueland et al. and a decrease in testosterone hormone level was observed after a 3.3 Gy dose (10th fraction) in rectal cancer patients treated with radiotherapy in 2 Gy × 23–25 fractions. In the RTOG-0630 study, it was recommended that a volume <50% of the testis should receive 3 Gy if there was a desire to preserve fertility. Bakkal et al. compared supine and prone treatment positions in patients with rectal cancer who were treated with CRT and concluded that the supine 4-field external beam radiotherapy allowed lower testicular doses than the prone 3-field and 4-field techniques. They reported that the reason was the greater distance between the lower edge of the field and the testes. Another study by Banaee et al. concluded that a testicular shield was a suitable device for reducing peripheral doses to the testes in patients with bladder, prostate, and rectal cancers. It provided a 40%–70% reduction in absorbed testes doses of patients treated with 18 MV photon beams. Our results showed that CRT in the prone position exceeded the dose constraint for testes defined by the RTOG-0630 study. In patients who are to be treated with CRT and desire to retain fertility, it is recommended to immobilize patients in the supine position with or without testicular shielding during radiotherapy or to recommend sperm banking before treatment.
Joye et al. reported that the prone position on a belly board was associated with reduced bowel doses during VMAT. In our clinic, rectal cancer patients are routinely treated on a belly board in the prone position to reduce bowel toxicity. According to our results on planning computed tomography imaging in the prone position, VMAT provided the best testis protection compared with CRT and DIMRT. Although the mean V3 values of the testes for IMRT and VMAT were below the RTOG-0630 study constraint, it was decreased by nearly 50% and 15% after VMAT compared with CRT and DIMRT, respectively. Although our study was a dosimetry comparison study and did not include clinical findings, we were unable to determine if the volume reached with the VMAT technique was sufficient or insufficient for testicular protection. Future studies should be designed for this purpose.
| > Conclusion|| |
Modern radiotherapy techniques were superior to conformal techniques in patients with rectal cancer. The best OAR protection was achieved with VMAT with the best target coverage, conformity, and heterogeneity using less treatment times. Testes, which are outside the target radiation volume, are exposed to radiation doses during radiotherapy. DIMRT and VMAT could be considered instead of conformal techniques in patients with rectal cancer, to preserve fertility.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| > References|| |
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
Gunderson LL, Tepper JE. Rectal cancer. In: Clinical Radiation Oncology. 4th
ed. Philadelphia, U.S.A.: Elsevier; 2016. p. 992-1018.
Roh MS, Colangelo LH, O'Connell MJ, Yothers G, Deutsch M, Allegra CJ, et al.
Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009;27:5124-30.
Li Y, Wang J, Ma X, Tan L, Yan Y, Xue C, et al.
A review of neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Int J Biol Sci 2016;12:1022-31.
Buchli C, Martling A, Arver S, Holm T. Testicular function after radiotherapy for rectal cancer – A review. J Sex Med 2011;8:3220-6.
Bruheim K, Guren MG, Skovlund E, Hjermstad MJ, Dahl O, Frykholm G, et al.
Late side effects and quality of life after radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 2010;76:1005-11.
Emmertsen KJ, Laurberg S. Low anterior resection syndrome score: Development and validation of a symptom-based scoring system for bowel dysfunction after low anterior resection for rectal cancer. Ann Surg 2012;255:922-8.
Birgisson H, Påhlman L, Gunnarsson U, Glimelius B. Late adverse effects of radiation therapy for rectal cancer – A systematic overview. Acta Oncol 2007;46:504-16.
Marijnen CA, van de Velde CJ, Putter H, van den Brink M, Maas CP, Martijn H, et al.
Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: Report of a multicenter randomized trial. J Clin Oncol 2005;23:1847-58.
Bruheim K, Svartberg J, Carlsen E, Dueland S, Haug E, Skovlund E, et al.
Radiotherapy for rectal cancer is associated with reduced serum testosterone and increased FSH and LH. Int J Radiat Oncol Biol Phys 2008;70:722-7.
Kandeel FR. The effects of chemotherapy and radiotherapy on testicular function. In: Male Reproductive Dysfunction: Pathophysiology and Treatment. 1st
ed. Boca Raton, Fl, U.S.A.: CRC Press; 2007. p. 235-44.
Buchli C, Al Abani M, Ahlberg M, Holm T, Fokstuen T, Bottai M, et al.
Assessment of testicular dose during preoperative radiotherapy for rectal cancer. Acta Oncol 2016;55:496-501.
Meistrich ML. Effects of chemotherapy and radiotherapy on spermatogenesis in humans. Fertil Steril 2013;100:1180-6.
Zhao J, Hu W, Cai G, Wang J, Xie J, Peng J, et al.
Dosimetric comparisons of VMAT, IMRT and 3DCRT for locally advanced rectal cancer with simultaneous integrated boost. Oncotarget 2016;7:6345-51.
Eade TN, Hanlon AL, Horwitz EM, Buyyounouski MK, Hanks GE, Pollack A. What dose of external-beam radiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys 2007;68:682-9.
Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: A meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 2009;74:1405-18.
Michalski JM, Yan Y, Watkins-Bruner D, Bosch WR, Winter K, Galvin JM, et al.
Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial. Int J Radiat Oncol Biol Phys 2013;87:932-8.
Mellon EA, Javedan K, Strom TJ, Moros EG, Biagioli MC, Fernandez DC, et al.
A dosimetric comparison of volumetric modulated arc therapy with step-and-shoot intensity modulated radiation therapy for prostate cancer. Pract Radiat Oncol 2015;5:11-5.
Dröge LH, Weber HE, Guhlich M, Leu M, Conradi LC, Gaedcke J, et al.
Reduced toxicity in the treatment of locally advanced rectal cancer: A comparison of volumetric modulated arc therapy and 3D conformal radiotherapy. BMC Cancer 2015;15:750.
Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, et al.
Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010;76:S10-9.
Wang D, Zhang Q, Eisenberg BL, Kane JM, Li XA, Lucas D, et al.
Significant reduction of late toxicities in patients with extremity sarcoma treated with image-guided radiation therapy to a reduced target volume: Results of Radiation Therapy Oncology Group RTOG-0630 trial. J Clin Oncol 2015;33:2231-8.
ICRU Report 83: Prescribing recording, and reporting photon, beam Intensity Modulated Radiation Therapy (IMRT). J ICRU 2010;10:1-106.
Robertson JM, Lockman D, Yan D, Wallace M. The dose-volume relationship of small bowel irradiation and acute grade 3 diarrhea during chemoradiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 2008;70:413-8.
Wen G, Zhang J, Chi F, Chen L, Huang S, Niu S, et al
. Dosimetric comparison of volumetric modulated arc therapy (VMAT), 5F Intensity Modulated Radiotherapy (IMRT) and 3D conformal radiotherapy (3DCRT) in rectal carcinoma receiving neoadjuvant chemoradiotherapy. Int J Med Phys Clin Eng Radiat Oncol 2015;4:54-63.
Shi J, Yang F, Ju X, Huang Y, Jiang F. Comparative study on dosimetry of VMAT and IMRT in assisted radiotherapy after radical resection of rectal cancer. Oncol Lett 2017;13:2971-4.
Feuvret L, Noël G, Mazeron JJ, Bey P. Conformity index: A review. Int J Radiat Oncol Biol Phys 2006;64:333-42.
Dominello MM, Kaufman I, McSpadden E, Snyder M, Zaki M, Maier J, et al
. Target volume heterogeneity index, a potentially valuable metric in IMRT prostate cancer treatment planning. J Nucl Med Radiat Ther 2014;5:192.
Teoh M, Clark CH, Wood K, Whitaker S, Nisbet A. Volumetric modulated arc therapy: A review of current literature and clinical use in practice. Br J Radiol 2011;84:967-96.
Rana S. Intensity modulated radiation therapy versus volumetric intensity modulated arc therapy. J Med Radiat Sci 2013;60:81-3.
Dueland S, Guren MG, Olsen DR, Poulsen JP, Magne Tveit K. Radiation therapy induced changes in male sex hormone levels in rectal cancer patients. Radiother Oncol 2003;68:249-53.
Bakkal BH, Vural T, Elmas O, Yildiz O, Kokturk F. Effect of treatment position and radiotherapy planning on testicular dose in patients with rectal carcinoma. J Cancer Res Ther 2014;10:558-62.
Banaee N, Nedaie HA, Esmati E, Nosrati H, Jamali M. Dose measurement outside of radiotherapy treatment field (Peripheral dose) using thermoluminesent dosimeters. Int J Radiat Res 2014;12:355-9.
Joye I, Verstraete J, Bertoncini C, Depuydt T, Haustermans K. Implementation of volumetric modulated arc therapy for rectal cancer: Pitfalls and challenges. Acta Oncol 2015;54:1677-81.
[Figure 1], [Figure 2]
[Table 1], [Table 2]